Neuropilin 1 expression in human aortas, coronaries and the main bypass grafts

European Journal of Cardio-thoracic Surgery

Volumn 46, Issue 6, 2014, Pages 967-973

  Alattar, Mohamed ^a   Jiang, Chunyang ^b   Luan, Zhou ^c   Pan, Tiecheng ^c   Liu, Ligang ^c   Li, Jun ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Tianjin Union Medical Center   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gene therapy; Intima hyperplasia; Neuropilin 1; Vein graft; Vessels

Indexed keywords

MESSENGER RNA; NEUROPILIN 1;

ADULT; ADVENTITIA; AGED; AORTA; ARTERY DYSPLASIA; ARTICLE; BYPASS SURGERY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CORONARY ARTERY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTIMAL HYPERPLASIA; MALE; MAMMARY ARTERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; SMOOTH MUSCLE; WESTERN BLOTTING; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BLOOD VESSEL PROSTHESIS; CORONARY ARTERY BYPASS GRAFT; CORONARY BLOOD VESSEL; GENETICS; INTIMA; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; AGED; AORTA; BLOOD VESSEL PROSTHESIS; BLOTTING, WESTERN; CORONARY ARTERY BYPASS; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPILIN-1; ORGAN SPECIFICITY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUNICA INTIMA;

EID: 84928195539     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu118     Document Type: Article

References (25)

1. Hata MSA, Niino T, Yoda M, Wakui S, Chiku M, Takayama T et al. What is the optimal management for preventing saphenous vein graft diseases? Early results of intravascular angioscopic assessment. Circ J 2007;71:286-7.
2. Friedl R, Li J, Schumacher B, Hanke H, Waltenberger J, Hannekum A et al. Intimal hyperplasia and expression of transforming growth factor-beta1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann Thorac Surg 2004;78:1312-8.
3. Wiedemann D, Kocher A, Bonaros N, Semsroth S, Laufer G, Grimm M et al. Perivascular administration of drugs and genes as a means of reducing vein graft failure. Curr Opin Pharmacol 2012;12:203-16.
4. Robertson KE, McDonald RA, Oldroyd KG, Nicklin SA, Baker AH. Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role?. Pharmacol Ther 2012;136:23-34.
5. Simons M. VEGF and restenosis: the rest of the story. Arterioscler Thromb Vasc Biol 2009;29:439-40.
6. Raja SG, Haider Z, Ahmad M, Zaman H. Saphenous vein grafts: to use or not to use?. Heart Lung Circ 2004;13:403-9.
7. Shukla N, Jeremy JY. Pathophysiology of saphenous vein graft failure: a brief overview of interventions. Curr Opin Pharmacol 2012;12:114-20.
8. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
9. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010;1804:567-80.
10. Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, Uemura A et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 2002;99:383-8.
11. Wang L, Dutta SK, Kojima T, Xu X, Khosravi-Far R, Ekker SC et al. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PloS ONE 2007;2:e1161.
12. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 2005;435:98-104.
13. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J et al. Response to letter regarding article, 'histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid'. Circulation 2013;127:e540.
14. Sulpice E, Plouet J, Berge M, Allanic D, Tobelem G, Merkulova-Rainon T. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 2008;111:2036-45.
15. Shintani Y, Takashima S, Asano Y, Kato H, Liao Y, Yamazaki S et al. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 2006;25:3045-55.
16. Pellet-Many C, Frankel P, Evans IM, Herzog B, Junemann-Ramirez M, Zachary IC. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J 2011;435:609-18.
17. West DC, Rees CG, Duchesne L, Patey SJ, Terry CJ, Turnbull JE et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 2005;280:13457-64.
18. Woodside KJ, Naoum JJ, Torry RJ, Xue XY, Burke AS, Levine L et al. Altered expression of vascular endothelial growth factor and its receptors in normal saphenous vein and in arterialized and stenotic vein grafts. Am J Surg 2003;186:561-8.
19. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J et al. Accelerated restitution of endothelial integrity and endotheliumdependent function after phVEGF165 gene transfer. Circulation 1996;94:3291-302.
20. Meinhart JG, Deutsch M, Fischlein T, Howanietz N, Froschl A, Zilla P. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann Thorac Surg 2001;71(5 Suppl):S327-31.
21. Zarge JI, Huang P, Husak V, Kim DU, Haudenschild CC, Nord RM et al. Fibrin glue containing fibroblast growth factor type 1 and heparin with autologous endothelial cells reduces intimal hyperplasia in a canine carotid artery balloon injury model. J Vasc Surg 1997;25:840-8; discussion 848-9.
22. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. New Engl J Med 1988;319:462-7.
23. Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M et al. The adventitia: essential regulator of vascular wall structure and function. Ann Rev Physiol 2013;75:23-47.
24. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007;38:258-68.
25. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-22.